UBS Group’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.08M | Sell |
|
|||||
|
2025
Q1 | $1.23M | Buy |
|
|||||
|
2024
Q4 | $1.82M | Buy |
|
|||||
|
2024
Q3 | $1.41M | Buy |
|
|||||
|
2024
Q2 | $539K | Sell |
|
|||||
|
2024
Q1 | $3.26M | Buy |
|
|||||
|
2023
Q4 | $659K | Buy |
|
|||||
|
2023
Q3 | $141K | Sell |
|
|||||
|
2023
Q2 | $1.24M | Sell |
|
|||||
|
2023
Q1 | $2.38M | Buy |
|
|||||
|
2022
Q4 | $2.95M | Buy |
|
|||||
|
2022
Q3 | $53K | Sell |
|
|||||
|
2022
Q2 | $1.3M | Sell |
|
|||||
|
2022
Q1 | $5.41M | Buy |
|
|||||
|
2021
Q4 | $7.49M | Buy |
|
|||||
|
2021
Q3 | $1.57M | Buy |
|
|||||
|
2021
Q2 | $1.35M | Sell |
|
|||||
|
2021
Q1 | $3.71M | Sell |
|
|||||
|
2020
Q4 | $7.98M | Buy |
|
|||||
|
2020
Q3 | $277K | Buy |
|
|||||
|
2020
Q2 | $179K | Sell |
|
|||||
|
2020
Q1 | $156K | Sell |
|
|||||
|
2019
Q4 | $1.01M | Sell |
|
|||||
|
2019
Q3 | $2.66M | Buy |
|
|||||
|
2019
Q2 | $780K | Buy |
|
|||||
|
2019
Q1 | $168K | Sell |
|
|||||
|
2018
Q4 | $1.13M | Buy |
|
|||||
|
2018
Q3 | $494K | Sell |
|
|||||
|
2018
Q2 | $1.15M | Buy |
|
|||||
|
2018
Q1 | $89K | Buy |
|
|||||
|
2017
Q4 | $37K | Buy |
|
|||||
|
2017
Q3 | $7K | Sell |
|
|||||
|
2017
Q2 | $141K | Buy |
|
|||||
|
2017
Q1 | – | Sell |
|
|||||
|
2016
Q4 | $2K | Sell |
|
|||||
|
2016
Q3 | $7K | Buy |
|
|||||
|
2016
Q2 | – | Sell |
|
|||||
|
2016
Q1 | $4K | Sell |
|
|||||
|
2015
Q4 | $14K | Buy |
|
|||||
|
2015
Q3 | $20K | Buy |
|
|||||
|
2015
Q2 | – | Sell |
|
|||||
|
2015
Q1 | $17K | Buy |
|
|||||
|
2014
Q4 | $11K | Buy |
|